Back to results
US 5,675,008 AGranted
Excitatory amino acid receptor antagonists
AssigneeEli Lilly and Company
InventorsCarl F. Bertsch, Bret Huff, Michael J. Martinelli, Paul L. Ornstein
Life of this patent
Estimating the term…
Abstract
This invention provides novel decahydroisoquinoline compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides synthetic methods for preparing decahydroisoquinolines, as well as, novel intermediates in the synthesis thereof.
Claims9
A process for the preparation of a compound of the formula ##STR87## wherein:
- R.sup.9 is acyl or alkoxycarbonyl;
- and
- R.sup.10 is hydrogen, C.sub.1 -C.sub.6 alkyl, or aryl;
- which comprises the steps of:
- (1) stereoselectively reducing a compound of formula ##STR88## wherein R.sup.9 and R.sup.10 are as defined previously, with a hydrogenation catalyst and hydrogen wherein the hydrogenation catalyst is rhodium on carbon, to produce a compound of the formula ##STR89## wherein R.sup.9 and R.sup.10 are as defined previously;
- and (2) oxidizing said formula VII compound.
3 more elements
Dependencies are inferred from the claim text.